Hongbin Zhou
Managing Director @ Legend Capital
Hongbin Zhou is a Series A investor at Legend Capital focused on Health Care and Biotechnology. Hongbin Zhou is based out of Beijing and is the director of Atour Hotel. Hongbin previously worked at Milkway Chemical Engineering Supply Chain Service as a director. Hongbin Zhou attended the Fudan University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Hongbin Zhou invests in
Stages Hongbin Zhou invests in
Countries Hongbin Zhou invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Biopharma 1 (25%)
- Consulting 1 (25%)
Stage
- Series A 1 (25%)
- Series B 1 (25%)
- Series C 1 (25%)
- Series E 1 (25%)
Country
- China 3 (75%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tripod Preclinical Research Laboratories
|
Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), foodadditives, biologics，pesticides，veterinary drugs, and new cosmetics. | $5.5M / Series C / Apr 12, 2023 | |
APTBIO
|
APTBIO was initiated by Shanghai Institutes for Biological Sciences under Chinese Academy of Sciences in 2004, and is mainly engaged in the application of mass spectrometry technology. The so-called mass spectrometry technology is to measure the quality of protein molecules to carry out the identification of protein molecules, the modification ofprotein molecules and the study of protein molecule interactions. | Series B / Aug 16, 2022 | |
ClinChoice
|
Fountain Medical Development Ltd., a contract research organization, provides ICH GCP compliant clinical research services for the multinational clients in China and the United States. It offers consulting, project management, regulatory affairs, clinical operations, central laboratory services, site management, biometrics, and clinical trialdesigns, as well as AE/SAE collection, review, assessment and reporting services, data and safety monitoring board handling, and signal detection services. The company is based in Beijing, China. | $150M / Series E / Jul 04, 2022 | |
Nest
|
Nest Bio is a manufacturer of disposable medical consumables, focusing on the R&D and production of cell culture consumables. | Series A / Jun 07, 2022 |
Co-Investors
About Legend Capital
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Legend Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hongbin Zhou
Managing Director
|
|||
Jianqing Wang
Managing Director and Chief Management Advisor
|
|||
Joon Park
Co-CIO
|
|||
Tony WANG
VP
|
|||
Yi Kang
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hongbin Zhou invest in?
Hongbin Zhou invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hongbin Zhou?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Hongbin Zhou last invest?
The most recent investment recorded for Hongbin Zhou closed in Apr 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
